sglt2 inhibitors and glp 1 receptor agonists GLP1 vs SGLT2-I in Preventing CKD in T2DM: An Interview – AJKD Blog Criteria for recommendation of SGLT2

Recent studies suggest that ALA IV therapy may also benefit individuals with Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH)

Glutation, oddajc witaminie C dwa protony, sprawia, i ponownie staje si ona aktywnym antyoksydantem

In this regard, the translational relevance of this preclinical study was demonstrated in patients with obesity by correlation of: (1) circulating FGF21 levels 4 weeks after mRYGB with the initial fat mass and one-year body weight reduction, (2) circulating FFAs with 4 week-body weight loss in mRYGB patients and (3) circulating adiponectin and OXM with weight loss

Additional activity at MC3R receptors involved in metabolic regulation